FIELD: chemistry.
SUBSTANCE: claimed invention relates to field of organic chemistry, namely to novel heterocyclic compounds of general formula (I) and to its pharmaceutically acceptable salt or its solvate, where R1 represents halogen atom, C1-4 alkyl group, C1-4 alkoxygroup, C1-4 halogenalkyl group, cyanogroup, carbamoyl group, R2 represents hydrogen atom, R3 represents C1-4 alkyl group, R4 represents hydrogen atom or C1-4 alkyl group, ring A represents (i) C3-6 monocyclic carbon ring, including phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclohexene, (iii) 5-6-membered monocyclic heterocyclic ring, containing one-two heteroatoms, selected from oxygen atom, nitrogen atom and sulphur atom, including thiophene, furan, isoxazole, imidazole, pyrazole, thiazole, pyridine or (iv) 9-membered bicycic heterocyclic ring, including indole, X represents nitrogen atom or carbon atom, T represents bond or linear C1-4 alkylene group, C2-4 alkenylene group or C2-4 alkinylene group, optionally substituted with two R5 (where R5 represents C1-4 alkyl group or aminogroup), U represents (i) methylene group, (ii)oxygen atom, (iii) -NR6- (where R6 represents hydrogen atom or methyl group) or (iv) 3-6-membered monocycle, including cyclobutane, cyclopentane, cyclohexane, phenyl, thiophene, pyrrolidine, pyrazole, imidazole, triazole, oxazole, piperazine, piperidine, tetrahydropyridine C7-8 bridge carbon ting, including bicyclooctane, bicycloheptane and imidazolidine, optionally substituted with one-three R7 (where R7 represents halogen atom, C1-4 alkyl group; hydroxygroup, C1-4 alkoxygroup or benzyloxy group), Y represents (i) bond or (ii) linear C1-3 alkylene group, optionally substituted with one or two R8 (where R8 represents methyl group), W represents bond or linear C1-3 alkylene group; Z represents methylene group, oxygen atom or sulphur atom, q represents integer number 1, r represents integer number from 0 to 5, and t represents integer number from 0 to 2, on condition that groups, represented by set R1, R2, R3, R5, R7 and R8, can be similar or different, respectively, and two R3 or R5, bound with one and the same carbon atom, can be taken together with carbon atom with formation of C3cycloalkyl, respectively. Invention also relates to pharmaceutical composition, pharmaceutical preparation and ENPP2 inhibitor, based on formula (I) compound.
EFFECT: novel compounds, possessing inhibiting activity with respect to ENPP2, have been obtained.
29 cl, 2 dwg, 3 tbl, 937 ex
Title | Year | Author | Number |
---|---|---|---|
HETEROCYCLIC INHIBITORS OF Hh-SYGNAL CASCADE, BASED ON THEM MEDICINAL COMPOSITIONS AND METHOD OF TREATING DISEASES INDUCED BY ABBARANT ACTIVITY OF Hh-SIGNAL SYSTEM | 2007 |
|
RU2364597C1 |
BICYCLIC HETEROCYCLIC COMPOUNDS AND USE THEREOF IN THERAPY | 2014 |
|
RU2696310C1 |
DERIVATIVES OF TRIAZOLO[1,4]DIAZEPINE AND METHODS OF THEIR SYNTHESIS | 1989 |
|
RU2117670C1 |
SPIROCYCLIC AZAINDOLE DERIVATIVES | 2007 |
|
RU2468028C2 |
SUBSTITUTED HYDRATED TIENO-PYRROLO [3,2-c] PYRIDINES, LIGANDS, PHARMACEUTICAL COMPOSITION AND ITS APPLICATION METHOD | 2010 |
|
RU2451686C1 |
HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | 2013 |
|
RU2671628C2 |
BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | 2012 |
|
RU2662827C2 |
PYRIDAZINONE DERIVATIVES AS PARP INHIBITORS | 2008 |
|
RU2490265C2 |
SUBSTITUTED PYRIMIDINETHIOALKYL OR ALKYLESTER COMPOUNDS AND METHOD OF INHIBITION OF VIRAL REVERSE TRANSCRIPTASE ACTIVITY | 1996 |
|
RU2167155C2 |
METHOD FOR TREATMENT OF ALLERGY BY USING SUBSTITUTED PYRAZOLES | 2001 |
|
RU2259202C2 |
Authors
Dates
2016-01-20—Published
2011-07-05—Filed